Parkinson's Progressive Markers Initiative Study (PPMI Study)

Clinical Trial Investigator: Tanya Simuni, MD

Aim: To identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. 

Eligible Subjects:

Hyposmia (loss of smell)


REM Behavior Disorder (RBD) - Sleep Disorder


Genetic Cohort-PD Subjects


Genetic Cohort—Unaffected Subjects

OR


Procedures: Blood draw, DatScan, MRI, Lumbar Puncture

Study Duration: Five years

Travel Compensation: Free parking at designated parking facilities. $50 or $200 depnding on visit procedures. Hotel stay available (depending on visit procedures) for out-of-towners

ALL STUDY RELATED MEDICATION/PROCEDURES ARE FREE OF CHARGE.

For More Information: Call us at (312) 503-0755, or email pdclinicaltrials@northwestern.edu.

Disclaimer

Northwestern Medicine and Northwestern University Feinberg School of Medicine will not release any of your personal information to 3rd parties, participating organizations and/or other institutions. Your information will only be available to the researcher(s) after you indicate interest in being contacted about a particular study.

Newly Diagnosed

Newly diagnosed with Parkinson’s disease and not yet treated? Please complete the Northwestern Medicine Parkinson’s Disease and Movement Disorders Center online appointment form to discuss next steps.

Feinberg is not a site of care. PDMDC faculty see patients through our affiliated clinic.